ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1054

Trends in CKD Prevalence in the KEEP Mexico from 2008 to 2017

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Obrador, Gregorio T., Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Raña, Alejandro, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Contreras Estrada, Daniela, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Aguilar, Diego J., Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Rubilar, Ximena Del carmen, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Olvera, Nadia, Sociedad de Asistencia Panamericana, MEXICO, Mexico
  • Sotelo, Alma, Sociedad de Asistencia Panamericana, MEXICO, Mexico
  • Lopez, Mariana, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Cuadra, Montserrat M., Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Jacob Kuttothara, Stefany, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Urquiza, Marselle, Universidad Panamericana, Mexico City, Mexico City, Mexico
  • Villa, Antonio, Universidad Panamericana, Mexico City, Mexico City, Mexico
Background

The Kidney Early Evaluation Program (KEEP) is a screening and educational program aimed at detecting CKD among adults with risk factors, such as DM, HTN, family history of these conditions or CKD. In 2008 the Mexican Kidney Foundation adapted KEEP; since then, 67 screening campaigns have been performed

Methods

Adults with DM, HTN, family history of DM, HTN, or CKD participated from 2008 to 2017. All completed a questionnaire and BP, weight, and height were measured. Albuminuria and serum creatinine were obtained, and GFR was estimated (CKD-EPI). Age-adjusted analyses were done to describe trends in CKD prevalence for almost a decade

Results

6,885 patients with risk factors for CKD participated in a single KEEP Mexico program from 2008 to 2017. Mean age of participants was 49.7 ± 14.5 years, 69% were women. Prevalence of DM and HTN were 36.9%, and 39.5% respectively. Mean duration of DM and HTN were 10.1 and 8.5 years respectively. CKD prevalence was 30.2%, with CKD 1-2 being the most frequent stages. CKD prevalence increased over the study period, particularly at the expense of stage 2. Prevalence of stage 1 decreased and of stages 3, 4 & 5 remained virtually unchanged. CKD prevalence among patients with DM, HTN, or both was 25.3%, 21%, and 33.2% respectively, and increased over time

Conclusion

CKD prevalence in the KEEP Mexico has increased over a decade, with the most significant increase in stage 2. CKD prevalence is higher in patients with both DM and HTN compared with those with either risk factor. Further analyses are being conducted to determine the factors associated with these trends. A longitudinal analysis of KEEP participants previously reported showed that a high proportion of patients who initially tested positive for CKD were eventually confirmed to have the disease